A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis

2015 ◽  
Vol 54 (7) ◽  
pp. 834-838 ◽  
Author(s):  
Siavash M. Shanehsaz ◽  
Silva Ishkhanian
Keyword(s):  
Comparative Study ◽  
Cutaneous Leishmaniasis ◽  
Low Dose ◽  
Standard Dose ◽  
Meglumine Antimoniate ◽  
Oral Cimetidine

scholarly journals FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

2014 ◽  
Vol 56 (4) ◽  
pp. 291-296 ◽  
Author(s):  
Madelon Novato Ribeiro ◽  
Maria Inês Fernandes Pimentel ◽  
Armando de Oliveira Schubach ◽  
Raquel de Vasconcellos Carvalhães de Oliveira ◽  
José Liporage Teixeira ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cutaneous Leishmaniasis ◽  
Low Dose ◽  
Lower Number ◽  
Adherence To Treatment ◽  
Simple Method ◽  
Meglumine Antimoniate ◽  
Factors Associated ◽  
Adherence Monitoring ◽  
Socioeconomic Data

The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. Between 2008 and 2011, 57 patients with CL were interviewed using a questionnaire to collect socioeconomic data. The following methods were used for adherence monitoring: counting of vial surplus, monitoring card, Morisky test and modified Morisky test (without the question regarding the schedule); we observed 82.1% (vial return), 86.0% (monitoring card), 66.7% (Morisky test) and 86.0% (modified Morisky test) adherence. There was a strong correlation between the method of vial counting and the monitoring card and modified Morisky test. A significant association was observed between greater adherence to treatment and low dose of MA, as well as with a lower number of people sleeping in the same room. We recommend the use of the modified Morisky test to assess adherence to treatment of CL with MA, because it is a simple method and with a good performance, when compared to other methods.

Comparative Study of Low Dose Conjugate Equine Estrogen 0.3 mg vs Standard Dose Conjugate Equine Estrogen 0.625 mg as Hormone Replacement Therapy

2013 ◽  
Vol 1 (2) ◽  
pp. 45-49
Author(s):  
Meeta Gupta ◽  
Poonam Yadav ◽  
Sarvesh Kumar
Keyword(s):  
Hormone Replacement Therapy ◽  
Comparative Study ◽  
Replacement Therapy ◽  
Low Dose ◽  
Standard Dose ◽  
Hormone Replacement ◽  
Mineral Density ◽  
Conjugate Equine Estrogen ◽  
Group A ◽  
Group B

ABSTRACT Introduction Since menopause was related to variety of genitourinary, vasomotor, psychological and musculoskeletal changes, conjugated equine estrogen (CEE) was introduced for all menopause-related symptoms in various doses. Materials and methods It is a comparative study in which 100 postmenopausal women were selected (natural or surgical menopause) with one or more menopausal symptoms. All patients were randomly divided in two groups. Group A received 0.3 mg CEE and group B received 0.625 mg CEE, and both groups were compared with each other in various aspects. Results Both the groups were comparable to each other with respect to mean age, residence, type of menopause, total duration of menopause. Both the groups show comparable improvement in vasomotor, genitourinary and psychological symptoms and p > 0.05 which is not significant. On evaluation of bone mineral density (BMD), the group B showed significant improvement than group A (p < 0.001). Effect on endometrium was not significant. Conclusion Because of the complications of estrogen ± progestin, it should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risk for individual women. How to cite this article Yadav P, Singh R, Kaur H, Gupta M, Kumar S. Comparative Study of Low Dose Conjugate Equine Estrogen 0.3 mg vs Standard Dose Conjugate Equine Estrogen 0.625 mg as Hormone Replacement Therapy. J South Asian Feder Menopause Soc 2013;1(2):45-49.

scholarly journals RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE

2014 ◽  
Vol 56 (4) ◽  
pp. 361-362 ◽  
Author(s):  
Erica de Camargo Ferreira e Vasconcellos ◽  
Maria Inês Fernandes Pimentel ◽  
Cláudia Maria Valete-Rosalino ◽  
Maria de Fátima Madeira ◽  
Armando de Oliveira Schubach
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Rio De Janeiro ◽  
Low Dose ◽  
Reference Center ◽  
Meglumine Antimoniate ◽  
Cutaneous Hypersensitivity ◽  
Intralesional Administration ◽  
The Right

We report a case of a 42 year-old female, who came to a leishmaniasis reference center in Rio de Janeiro, Brazil, presenting a cutaneous leishmaniasis lesion in the right forearm. Treatment with low-dose intramuscular meglumine antimoniate (MA) (5 mg Sb5+/kg/day) was initiated, with improvement after 28 days, although with the development of generalized eczema. After 87 days, the lesion worsened. Patient refused treatment with amphotericin B. MA was then infiltrated in the lesion, in two sessions, resulting in local eczema, with bullae formation; however, twenty days after, both the ulcer and eczema receded. Intralesional administration of MA should be used carefully when previous cutaneous hypersensitivity is detected.

Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate

2002 ◽  
Vol 41 (7) ◽  
pp. 441-443 ◽  
Author(s):  
Ali Z. Momeni ◽  
Mohamad Reza Reiszadae ◽  
Malihalsadat Aminjavaheri
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Low Dose ◽  
Meglumine Antimoniate
Sign in / Sign up

Export Citation Format

Share Document